

## COMPANY STATEMENT

### MITSUBISHI TANABE PHARMA CANADA, INC. TO DISCONTINUE RADICAVA® IV (edaravone)

*~MTP-CA continues to market the oral formulation, RADICAVA® Oral Suspension~*

**TORONTO, ON, October 10, 2024** – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced the strategic business decision to discontinue RADICAVA® IV (edaravone), an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS) that was granted market authorization by Health Canada in October 2018. RADICAVA® IV is not being discontinued for reasons of safety or effectiveness.

The distribution of RADICAVA® IV will end as early as April 1, 2025, in Canada. Fewer people living with ALS are still using RADICAVA® IV, and these patients should consult with their physician to determine how to best transition to an alternative treatment plan.

MTP-CA continues to market the oral formulation, RADICAVA® Oral Suspension. The efficacy of RADICAVA® Oral Suspension is based on a comparative bioavailability study in healthy subjects with RADICAVA® Oral Suspension and RADICAVA® IV. RADICAVA® Oral Suspension demonstrated similar pharmacokinetics following oral administration or via feeding tube.<sup>1,2</sup>

For more information, including the full [Product Monograph](#), please visit [www.radicava.ca](http://www.radicava.ca).

#### **About RADICAVA® IV and RADICAVA® Oral Suspension (edaravone)**

RADICAVA® IV and RADICAVA® Oral Suspension are indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA® was approved by the U.S. Food and Drug Administration (FDA) in May of 2017. Marketing authorization for RADICAVA® IV Infusion was granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), and Malaysia (December 2021).

RADICAVA® ORS (edaravone) was approved by the U.S. FDA in May 2022. RADICAVA® Oral Suspension (edaravone) was authorized by Health Canada in November 2022.

**About Mitsubishi Tanabe Pharma Canada, Inc.**

Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit [www.mt-pharma-ca.com](http://www.mt-pharma-ca.com).

**About Mitsubishi Tanabe Pharma America, Inc.**

Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit [www.mt-pharma-america.com](http://www.mt-pharma-america.com) or follow us on [X \(formerly Twitter\)](#), [Facebook](#) and [LinkedIn](#).

**References:**

---

<sup>1</sup> RADICAVA® Product Monograph. Mitsubishi Tanabe Pharma America, Inc.; 2022.

<sup>2</sup> Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2017;16(7):505-512.